Equities research analysts expect that HTG Molecular Diagnostics Inc (NASDAQ:HTGM) will announce ($0.19) earnings per share (EPS) for the current fiscal quarter, according to Zacks Investment Research. Two analysts have made estimates for HTG Molecular Diagnostics’ earnings, with estimates ranging from ($0.19) to ($0.18). HTG Molecular Diagnostics reported earnings per share of ($0.46) during the same quarter last year, which suggests a positive year over year growth rate of 58.7%. The company is scheduled to report its next earnings results on Tuesday, November 6th.
According to Zacks, analysts expect that HTG Molecular Diagnostics will report full year earnings of ($0.70) per share for the current year, with EPS estimates ranging from ($0.79) to ($0.63). For the next year, analysts expect that the firm will post earnings of ($0.50) per share, with EPS estimates ranging from ($0.57) to ($0.45). Zacks Investment Research’s earnings per share calculations are a mean average based on a survey of research analysts that that provide coverage for HTG Molecular Diagnostics.
HTG Molecular Diagnostics (NASDAQ:HTGM) last released its earnings results on Thursday, August 9th. The medical research company reported ($0.14) earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.19) by $0.05. HTG Molecular Diagnostics had a negative return on equity of 132.67% and a negative net margin of 81.10%. The company had revenue of $4.91 million for the quarter, compared to analysts’ expectations of $5.30 million.
Several research firms have issued reports on HTGM. ValuEngine upgraded HTG Molecular Diagnostics from a “hold” rating to a “buy” rating in a research report on Tuesday, July 3rd. HC Wainwright set a $7.00 price target on HTG Molecular Diagnostics and gave the stock a “buy” rating in a report on Monday, July 2nd. Zacks Investment Research upgraded HTG Molecular Diagnostics from a “hold” rating to a “buy” rating and set a $4.00 price target on the stock in a report on Tuesday, August 14th. Finally, Leerink Swann restated an “outperform” rating on shares of HTG Molecular Diagnostics in a report on Monday, July 9th. One investment analyst has rated the stock with a hold rating and five have issued a buy rating to the stock. The company has an average rating of “Buy” and a consensus target price of $6.25.
NASDAQ HTGM opened at $3.66 on Tuesday. The company has a current ratio of 9.50, a quick ratio of 9.29 and a debt-to-equity ratio of 0.35. HTG Molecular Diagnostics has a 12-month low of $1.71 and a 12-month high of $5.83.
Several institutional investors and hedge funds have recently added to or reduced their stakes in HTGM. Stonepine Capital Management LLC acquired a new stake in shares of HTG Molecular Diagnostics in the 2nd quarter worth approximately $5,506,000. Putnam Investments LLC grew its holdings in shares of HTG Molecular Diagnostics by 31.4% in the 2nd quarter. Putnam Investments LLC now owns 1,387,883 shares of the medical research company’s stock worth $4,524,000 after acquiring an additional 331,690 shares during the period. Spark Investment Management LLC acquired a new stake in shares of HTG Molecular Diagnostics in the 2nd quarter worth approximately $663,000. GSA Capital Partners LLP acquired a new stake in shares of HTG Molecular Diagnostics in the 2nd quarter worth approximately $650,000. Finally, EAM Global Investors LLC acquired a new stake in shares of HTG Molecular Diagnostics in the 1st quarter worth approximately $684,000. Institutional investors and hedge funds own 49.17% of the company’s stock.
About HTG Molecular Diagnostics
HTG Molecular Diagnostics, Inc develops and markets products and services based on proprietary technology that facilitates the routine use of targeted molecular profiling. The company offers instrumentation (or platforms); consumables comprising assay kits; and software analytics that automate sample processing and profiles various molecular targets.
Featured Story: Average Daily Trade Volume – What It Means In Stock Trading
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for HTG Molecular Diagnostics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for HTG Molecular Diagnostics and related companies with MarketBeat.com's FREE daily email newsletter.